P. Richards

Phase III study of iniparib plus gemcitabine and carboplatin versus gemcitabine and carboplatin in patients with metastatic triple-negative breast cancer.

E. Winer, N. Robert, R. Carlson, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II trial of weekly nab-paclitaxel in combination with bevacizumab as first-line treatment in metastatic breast cancer

David A. Smith, N. Robert, M. Danso, 2008 .

245PDDuration of response and tumor shrinkage with first-line ribociclib + letrozole in postmenopausal women with HR+, HER2– ABC

P. Ward, F. Esteva, M. Campone, 2017 .

Outcomes in patients (pts) aged ≥65 years in the phase 3 ASCENT study of sacituzumab govitecan (SG) in metastatic triple-negative breast cancer (mTNBC).

A. Bardia, H. Rugo, S. Loibl, 2021 .

265P Study of samuraciclib (CT7001), a first-in-class, oral, selective inhibitor of CDK7, in combination with fulvestrant in patients with advanced hormone receptor positive HER2 negative breast cancer (HR+BC)

W. Gradishar, Siraj M. Ali, J. O’Shaughnessy, 2021, Annals of Oncology.

Safety data from a phase II trial of weekly nab-paclltaxel In combination with bevacizumab as first-line treatment In metastatlc breast cancer

David A. Smith, N. Robert, M. Danso, 2008 .

First-line ribociclib plus letrozole in postmenopausal women with HR+ , HER2− advanced breast cancer: Tumor response and pain reduction in the phase 3 MONALEESA-2 trial

P. Ward, F. Esteva, M. Campone, 2018, Breast Cancer Research and Treatment.

Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin lymphoma.

J. Hainsworth, H. Burris, F. Greco, 2000, Blood.

Talactoferrin alfa versus placebo in patients with refractory advanced non-small-cell lung cancer (FORTIS-M trial).

J. S. Lee, D. R. Berry, G. Giaccone, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib

Simak Ali, P. Ward, J. O’Shaughnessy, 2023, Nature communications.